Trial Profile

POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2026 According to GentiBio media release, company plans to present findings from the POLARIS study in the latter part of 2026 and the first half of 2027.
18 Mar 2026 According to GentiBio media release, company announced that the first participant has been dosed in this study, The trial is enrolling at 10 specialized clinical sites with expertise in cell-based immunotherapies across the U.S., with the first patient dosed at the University of North Carolina, Chapel Hill.
23 Jan 2026 According to GentiBio media release, company announced that Breakthrough T1D, with support in part from The Leona M. and Harry B. Helmsley Charitable Trust, has awarded a grant to support the companys POLARIS clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com